Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accounts Payables (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Accounts Payables data on record, last reported at $1.2 million in Q3 2025.

  • For Q3 2025, Accounts Payables fell 33.64% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, down 33.64%, while the annual FY2024 figure was $679000.0, 55.48% down from the prior year.
  • Accounts Payables reached $1.2 million in Q3 2025 per CRVS's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $4.2 million in Q3 2022 and bottomed at $432000.0 in Q1 2025.
  • Average Accounts Payables over 4 years is $1.8 million, with a median of $1.6 million recorded in 2024.
  • The widest YoY moves for Accounts Payables: up 158.62% in 2025, down 73.15% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $2.0 million in 2022, then dropped by 22.82% to $1.5 million in 2023, then crashed by 55.48% to $679000.0 in 2024, then surged by 83.06% to $1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $1.2 million in Q3 2025, $3.1 million in Q2 2025, and $432000.0 in Q1 2025.